BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31884151)

  • 21. A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.
    Bhunia N; Abu-Arja R; Stanek JR; Mehyar LS; Shaw PJ; Kang HJ; Stein J; O'Brien TA; Roberts CH; Lee AC; Loeb DM; Ozkaynak MF; Dalal JD; Strahlendorf C; Goyal RK; Shenoy SS; Rangarajan HG
    Transfusion; 2021 Mar; 61(3):894-902. PubMed ID: 33475172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
    Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients.
    He D; Zhu C; Guo X; Huang X; Han X; Zheng G; Zhao Y; Yang Y; Wu W; Ge J; Zhang E; He J; Cai Z
    Transfus Apher Sci; 2023 Jun; 62(3):103618. PubMed ID: 36481258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
    Chen J; Yuan LL; Zhang X; Qiao JL; Yin QX; Zhang YM; Yang XL; Cao XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
    Micallef IN; Sinha S; Gastineau DA; Wolf R; Inwards DJ; Gertz MA; Hayman SR; Hogan WJ; Johnston PB; Lacy MQ; Ansell SM; Buadi F; Dingli D; Dispenzieri A; Litzow MR; Porrata LF; Winters JL; Kumar S
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
    Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
    Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
    Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
    Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
    He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
    Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How to manage poor mobilisers.
    Worel N
    Transfus Apher Sci; 2024 Jun; 63(3):103934. PubMed ID: 38678982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma.
    Taenaka R; Takigawa K; Okamura K; Obara T; Nishimura N; Kohno K; Aoki K; Ogawa R
    Transfus Apher Sci; 2021 Dec; 60(6):103279. PubMed ID: 34563457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.
    Yuan S; Nademanee A; Krishnan A; Kogut N; Shayani S; Wang S
    Transfusion; 2013 Dec; 53(12):3244-50. PubMed ID: 23607889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
    D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
    Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.
    Douglas KW; Gilleece M; Hayden P; Hunter H; Johnson PRE; Kallmeyer C; Malladi RK; Paneesha S; Pawson R; Quinn M; Raj K; Richardson D; Robinson S; Russell N; Snowden J; Sureda A; Tholouli E; Thomson K; Watts M; Wilson KM
    J Clin Apher; 2018 Feb; 33(1):46-59. PubMed ID: 28631842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plerixafor: a peripheral blood stem cell mobilizer.
    Kessans MR; Gatesman ML; Kockler DR
    Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis.
    Dill V; Blüm P; Lindemann A; Biederstädt A; Högner M; Götze KS; Bassermann F; Hildebrandt M
    Transfusion; 2024 May; 64(5):871-880. PubMed ID: 38600674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
    Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
    Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.